The market correctly sees biology's potential but often misunderstands its timeline. Even with AI, biology is fundamentally harder and slower than software. Daniel Fero warns this mismatch in "tempo" expectations leads to over-funding hype cycles while under-funding foundational companies that are simply moving at the pace required for rigorous biological R&D.

It's a fool's errand to predict specific trial results. A robust quantitative approach to biotech focuses on underlying drivers and base rates. It positions a portfolio so the random, unpredictable nature of trial events plays out favorably over time, guided by factors like valuation and specialist ownership.

Experts express skepticism about the scientific value of AI-powered clinical trial prediction markets. The primary concern is that they function more as sophisticated betting platforms than tools to advance medicine. Their predictive power may not surpass the collective intelligence already embedded in public stock prices.

Private VCs with board seats operate deterministically, using their influence to 'make sure' a drug succeeds. Public fund managers operate probabilistically, accepting imperfect information in exchange for liquidity. They must calculate the odds of success rather than trying to directly shape the outcome.

In biotech, early data is often ambiguous. Instead of judging programs on potential, leaders must prioritize based on the time and capital required to reach a clear 'yes' or 'no' outcome. Indefinite 'gray zone' projects drain resources that could fund a winner.

The market currently rewards development-stage biotechs with high-potential pipeline catalysts more than profitable companies facing drug launch complexities. Investors are drawn to the upside of a "golden ticket" clinical result, finding it more attractive than modeling quarterly sales, inventory, and other commercial realities.

To maintain objectivity in acquisitions, Bending Spoons separates assumption-setting from model output. The team rigorously debates and locks in all inputs without seeing the projected P&L or IRR. This prevents the common bias of tweaking assumptions to justify a desired outcome. The final model output is then treated as unchangeable.

VC Bruce Booth warns that investors without deep biotech R&D experience are backing AI-driven drug discovery companies at inflated valuations. He predicts many will 'get their hands burned' due to flawed assumptions about value creation in the sector.

While data analysis is crucial, it's impossible to analyze everything before making a decision. Experienced leaders learn to trust their gut feeling, as exhaustive analysis rarely changes the final outcome but causes significant delays. Furthermore, the personal chemistry between business partners is a critical, often underestimated, factor for success.